A Phase 2 interventional study of Prolonged Exposure and Cannabidiol in PTSD, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.
Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 72nd largest by enrollment of the 246 interventional ones that give a count, is one of 25 that started in 2019, is one of 23 in phase 2, and was the 124th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22–70
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–75
VA Office of Research and Development · Sites in United States
Ages 18–75
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
263 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 30 · Phase 3 10 · Phase 4 14
First in 2000; this study’s year is marked. 25 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 87 across the 246 interventional studies, 110 across the 17 observational. Of the 194 that completed or were terminated, 167 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
22 of the studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06000475VA Office of Research and DevelopmentEnhancing Memory in Cognitive Processing Therapy for PTSD | 2026-12-31 |
| NCT05812131VA Office of Research and DevelopmentCOPEWeb Training for Providers | 2027-01-01 |
| NCT05149534VA Office of Research and DevelopmentrTMS-augmented Written Exposure Therapy for PTSD | 2027-01-29 |
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT05267665VA Office of Research and DevelopmentFamily Involvement in Treatment for PTSD (FIT-PTSD): A Brief, Feasible Method for Enhancing Outcomes, Retention, and Engagement | 2027-03-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and innovative next step for augmenting existing treatments and developing novel pharmacotherapy for PTSD. Findings from the proposed RCT will inform clinical practice and policy by investigating whether administration of CBD in the context of PE therapy will improve treatment outcomes for military Veterans with PTSD.
Prolonged exposure therapy (PE) is among the most efficacious treatments for PTSD and is designated as a VA/DoD frontline treatment. However, PE does not always lead to clinically meaningful symptom reductions in Veterans with PTSD. Successful PE treatment relies on extinction learning, which is often impaired in patients with PTSD. Cannabidiol (CBD) is a non-intoxicating phytocannabinoid. Administration of specific phytocannabinoids, like CBD, increase extinction learning in patients with PTSD, and could increase the speed and effectiveness of PE therapy. CBD also modulates 5-HT1A, which may directly improve hyperarousal/insomnia symptoms, and improve engagement and retention in treatment. Given these findings, adjunctive administration of CBD+PE could improve response rates to PE and reduce the number of sessions of PE needed to reach clinically meaningful change. The proposed study is designed to test the efficacy of using CBD in conjunction with PE for the treatment of PTSD in US Military Veterans. A randomized, controlled, double-blind study will compare Veterans who receive PE+CBD to PE+placebo. Participants will include 136 male and female Veterans from all service eras with PTSD. The primary hypothesis is that PE+CBD will reduce PTSD symptoms to a greater degree than PE+placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Psychotherapy plus active medication
Behavioral: Prolonged Exposure · Drug: Cannabidiol
Psychotherapy plus placebo medication
Behavioral: Prolonged Exposure · Drug: placebo
psychotherapy
Also known as: PE
active medication
Also known as: CBD
non-active medication
Clinician-Administered PTSD Scale DSM 5 (CAPS-5)
Change in PTSD Symptoms will be assessed by change in Total Severity Score (summed severity ratings on items 1-20) on the Clinician-Administered PTSD Scale DSM 5 (CAPS-5); CAPS-5 Total Severity scores range from 0 to 80; Higher scores indicate higher severity.
Time frame: Baseline, Post Treatment (16-weeks), 1-Month Follow-up (20-weeks), 3-Month Follow-up (28-weeks)
PTSD Checklist (PCL-5)
Rate of PTSD symptom reduction will be assessed by comparing the time-to-event of clinical response to treatment. The time-to-event is defined by number of PE sessions completed before patient achieves a 10-point reduction from baseline in total (summed) PTSD Checklist scores (PCL-5). PCL-5 Total Scores range from 0 to 80; Higher scores indicate worse functioning.
Time frame: Baseline, Weekly (up to 16-weeks)
Participants were recruited for a randomized, double-blind clinical trial evaluating cannabidiol as an adjunct to prolonged exposure therapy for PTSD in Veterans.
| Milestone | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo |
|---|---|---|
| Started | 50 | 46 |
| Completed | 27 | 31 |
| Not completed | 23 | 15 |
| Withdrew: Spouse died | 1 | 0 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Withdrawal by subject | 17 | 11 |
| Withdrew: Declined to talk about trauma | 0 | 1 |
Change in PTSD Symptoms will be assessed by change in Total Severity Score (summed severity ratings on items 1-20) on the Clinician-Administered PTSD Scale DSM 5 (CAPS-5); CAPS-5 Total Severity scores range from 0 to 80; Higher scores indicate higher severity.
| Score | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo |
|---|---|---|
| Baseline | 36.92 ± 8.96 | 35.05 ± 8.63 |
| Post Treatment (16 weeks) | 22.55 ± 14.86 | 23.07 ± 11.88 |
| 1-Month Follow-up (20 weeks) | 22.86 ± 14.25 | 21.48 ± 12.74 |
| 3-Month Follow-up (28 weeks) | 21.17 ± 14.64 | 21.93 ± 14.15 |
Rate of PTSD symptom reduction will be assessed by comparing the time-to-event of clinical response to treatment. The time-to-event is defined by number of PE sessions completed before patient achieves a 10-point reduction from baseline in total (summed) PTSD Checklist scores (PCL-5). PCL-5 Total Scores range from 0 to 80; Higher scores indicate worse functioning.
| PE sessions | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo |
|---|---|---|
| PTSD Checklist (PCL-5) | 5 (3 to 7) | 5 (3 to 5) |
Collected over From initiation of study medication through Week 16.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prolonged Exposure + Cannabidiol | 0/46 (0%) | 0/46 (0%) | 11/46 (23.9%) |
| Prolonged Exposure + Placebo | 0/45 (0%) | 0/45 (0%) | 15/45 (33.3%) |
| Event | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo |
|---|---|---|
| FatigueGeneral disorders | 6/46 | 8/45 |
| HeadacheNervous system disorders | 3/46 | 6/45 |
| Dry mouthGastrointestinal disorders | 3/46 | 3/45 |
| NauseaGastrointestinal disorders | 0/46 | 3/45 |
| SomnolenceNervous system disorders | 3/46 | 2/45 |
| Age, Continuous(Years) | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo | Total |
|---|---|---|---|
| Mean | 40.32 ± 13.76 | 45.54 ± 14.41 | 42.82 ± 14.24 |
| Sex: Female, Male(Participants) | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 34 | 32 | 66 |
| Race (NIH/OMB)(Participants) | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Black or African American | 7 | 6 | 13 |
| White | 35 | 33 | 68 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 12 | 26 |
| Not Hispanic or Latino | 32 | 34 | 66 |
| Unknown or Not Reported | 4 | 0 | 4 |
| CAPS-5 Total Severity Score(Score) | Prolonged Exposure + Cannabidiol | Prolonged Exposure + Placebo | Total |
|---|---|---|---|
| Mean | 36.92 ± 8.96 | 35.05 ± 8.63 | 36.03 ± 8.81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Sep 2025, 71 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's 71 months is above that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Stress Disorders, Post-Traumatic →
VA Office of Research and Development →